Number of | Percent with outcome | |||||
---|---|---|---|---|---|---|
Outcome - daily dose | Studies | Participants | Pregabalin | Placebo | Relative risk (95% CI) | NNH (95% CI) |
At least one adverse event | ||||||
150 mg | 2 | 449 | 77 | 71 | 1.2 (0.97 to 1.4) | not calculated |
300 mg | 8 | 2190 | 82 | 67 | 1.2 (1.17 to 1.29) | 6.6 (5.4 to 8.7) |
450 mg | 4 | 1379 | 90 | 74 | 1.2 (1.15 to 1.27) | 6.3 (5.1 to 8.5) |
600 mg | 9 | 2540 | 83 | 67 | 1.3 (1.25 to 1.37) | 6.1 (5.1 to 7.7) |
At least one serious adverse event | ||||||
150 mg | 3 | 542 | 4.1 | 4.0 | 1.0 (0.5 to 2.3) | not calculated |
300 mg | 8 | 1566 | 3.6 | 2.9 | 1.2 (0.7 to 2.1) | not calculated |
450 mg | 2 | 740 | 2.7 | 1.6 | 1.7 (0.6 to 4.5) | not calculated |
600 mg | 9 | 2101 | 3.7 | 3.2 | 1.2 (0.7 to 1.8) | not calculated |